BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Mar 2, 2015
Emerging Company Profile

The road to Tau

Asceneuron S.A. is working to treat neurodegeneration by preventing formation of neurofibrillary tangles in the hopes this mechanism will fare better in treating Alzheimer's disease than amyloid-targeted products. Neurofibrillary tangles arise when microtubule-associated protein tau...
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Dermatology

...In human keratinocytes cultured in hyperglycemic conditions, wound closure was delayed and general levels of O-GlcNAc...
...targeting OGT, the enzyme that adds O-GlcNAc to intracellular proteins, accelerated wound closure and decreased O-GlcNAc...
BioCentury | Feb 17, 2011
Tools & Techniques

Engineering protein stability

Two American teams have proposed distinct strategies to improve the stability of recombinant proteins. The techniques could be used to increase the manufacturing yield, shelf life and potentially the duration of efficacy of biologics, including...
BioCentury | May 10, 2004
Company News

BTG International plc, King's College deal

BGC acquired two development programs from the college. The first is BGC20-0402, which inhibits Core 2 GlcNAc-Transferase, an enzyme involved in the development of diabetic retinopathy. The second is a series of compounds aimed at...
BioCentury | Mar 5, 2001
Emerging Company Profile

Novazyme: Getting the translation right

The point of doing targeted therapy is that it generally requires a smaller amount of medication compared to systemic therapy, which relies on diffusion of drug to the site of action. Novazyme Inc. is trying...
BioCentury | Jan 18, 1999
Emerging Company Profile

GlycoDesign: On familiar ground

Proteins are the rage as targets for therapeutic development, but other molecules play pivotal roles in functions such as intercellular signaling. Carbohydrates, for example, participate in signal recognition on cell surfaces as part of glycoprotein...
BioCentury | Oct 19, 1998
Company News

Cytel, Japan Tobacco, Marukin Shoyu Co. Ltd. deal

CYTL entered into enzyme technology supply agreements with the Japanese companies to develop improvements to CYTL's Sugar Nucleotide Cycling (SNC) carbohydrate synthesis technology, for large-scale production. In particular, CYTL will focus on sialyl lactose, its...
BioCentury | Jul 29, 1996
Company News

Alexion other research news

A review of previously published work described how removal of a key antigenic site on foreign organs, cells, tissues and viruses can allow graft acceptance and improve the action of gene therapies with certain retroviral...
Items per page:
1 - 10 of 10